Sustainability | September 17, 2024
Piramal Pharma's GHG Commitment Validated and Approved by SBTi
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Target identification will commence on 17 September 2024, following the timeline provided in the campaign guidelines
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival
Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
This aims to benefit approximately 4.5 crore families with six crore senior citizens with Rs. 5 lakh free health insurance cover on a family basis
ALS patients experience neuroinflammation and rapid neurodegeneration
Subscribe To Our Newsletter & Stay Updated
